Travere Therapeutics (TVTX)

• Market cap: $1.61B
• 1 day: 2.38%
• 5 days: -1.07%
• 1 month: 6.93%
• 3 months: 6.19%
• 6 months: 88.79%
• Year to date: -2.37%
• 1 year: 108.09%
• 5 years: 20.18%
• 10 years: 40.20%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.

Employees: 380

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

51% more capital invested

Capital invested by funds: $771M [Q2] → $1.17B (+$396M) [Q3]

50% more funds holding in top 10

Funds holding in top 10: 2 [Q2] → 3 (+1) [Q3]

21% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 24

2% more funds holding

Funds holding: 172 [Q2] → 176 (+4) [Q3]

9% more repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 57

12.17% less ownership

Funds ownership: 121.24% [Q2] → 109.06% (-12.17%) [Q3]

17% less call options, than puts

Call options by funds: $12.4M | Put options by funds: $14.9M

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $20 8% upside
• Avg. target: $24 30% upside
• High target: $27 46% upside

4 analyst ratings

• positive: 3 75%
• neutral: 1 25%
• negative: 0 0%

Piper Sandler Allison Bratzel 82% 1-year accuracy 9 / 11 met price target	19% upside $22	Neutral Maintained	14 Nov 2024
Scotiabank Greg Harrison 44% 1-year accuracy 12 / 27 met price target	46% upside $27	Sector Outperform Maintained	1 Nov 2024
Barclays Carter Gould 37% 1-year accuracy 14 / 38 met price target	8% upside $20	Overweight Maintained	1 Nov 2024
Wells Fargo Mohit Bansal 42% 1-year accuracy 11 / 26 met price target	46% upside $27	Overweight Upgraded	21 Oct 2024